A detailed history of Black Rock Inc. transactions in Pulmonx Corp stock. As of the latest transaction made, Black Rock Inc. holds 3,037,266 shares of LUNG stock, worth $19.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,037,266
Previous 3,117,063 2.56%
Holding current value
$19.3 Million
Previous $39.7 Million 29.16%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$8.71 - $14.65 $695,031 - $1.17 Million
-79,797 Reduced 2.56%
3,037,266 $28.2 Million
Q4 2023

Feb 13, 2024

BUY
$7.89 - $13.14 $1.43 Million - $2.38 Million
181,403 Added 6.18%
3,117,063 $39.7 Million
Q3 2023

Nov 13, 2023

BUY
$9.88 - $14.0 $236,072 - $334,516
23,894 Added 0.82%
2,935,660 $30.3 Million
Q2 2023

Aug 11, 2023

BUY
$10.78 - $13.65 $2.22 Million - $2.81 Million
205,821 Added 7.61%
2,911,766 $38.2 Million
Q1 2023

May 12, 2023

BUY
$7.49 - $12.54 $92,164 - $154,304
12,305 Added 0.46%
2,705,945 $30.3 Million
Q4 2022

Feb 13, 2023

BUY
$4.92 - $17.35 $1.11 Million - $3.91 Million
225,355 Added 9.13%
2,693,640 $22.7 Million
Q3 2022

Nov 14, 2022

BUY
$15.35 - $23.99 $582,808 - $910,852
37,968 Added 1.56%
2,468,285 $41.1 Million
Q2 2022

Aug 12, 2022

SELL
$14.0 - $27.95 $4.62 Million - $9.22 Million
-329,738 Reduced 11.95%
2,430,317 $35.8 Million
Q1 2022

May 12, 2022

BUY
$21.13 - $35.65 $881,628 - $1.49 Million
41,724 Added 1.53%
2,760,055 $68.5 Million
Q4 2021

Feb 10, 2022

SELL
$29.72 - $45.1 $579,183 - $878,908
-19,488 Reduced 0.71%
2,718,331 $87.2 Million
Q3 2021

Nov 09, 2021

BUY
$35.98 - $44.48 $14.9 Million - $18.4 Million
414,180 Added 17.82%
2,737,819 $98.5 Million
Q2 2021

Aug 11, 2021

BUY
$37.61 - $48.0 $87.4 Million - $112 Million
2,323,639 New
2,323,639 $103 Million

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.